Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Myelodysplastic Syndromes Clinical Trial

Official title:

A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01904682
• Other study ID #: Onconova 09-07
• Secondary ID: 2013-000672-15
• Status: Completed
• Phase: Phase 2
• Start date: July 2013
• Est. completion date: May 2021

Study information

• Verified date: June 2021
• Source: Onconova Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will enroll low risk MDS patients who need red blood cell transfusions and who are refractory to or are not using erythropoiesis-stimulating agents. The purpose of the study is to determine whether oral rigosertib treatment results in hematological improvements according to the 2006 International Working Group criteria in these patients. The study will also record any side effects that may occur during the study.

Description:

This will be a Phase II, single-arm, multicenter study (approximately 15 centers). Approximately 40 transfusion-dependent patients with Low- or Int-1 risk Myelodysplastic Syndrome (MDS) by International Prognostic Scoring System (IPSS) will be enrolled and treated with oral rigosertib administered twice daily for 21 consecutive days of a 21-day cycle (continuous regimen) in order to obtain at least 35 evaluable patients treated for at least 8 weeks. Patients will take 560 mg rigosertib (two 280 mg capsules) in the morning and 280 mg (one 280 mg capsule) in the afternoon, in fasting conditions. All patients on intermittent regimen at the time of Amendment 2 of the Protocol will be switched to the continuous regimen, including patients on reduced doses.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: May 2021
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of MDS according to World Health Organization (WHO) criteria (Appendix 2) or French-American-British (FAB) classification that must be confirmed by bone marrow (BM) aspirate and/or biopsy within 6 weeks prior to Screening.

• Myelodysplastic syndrome (MDS) classified as Low risk or Int-1 risk, according to International Prognostic Scoring System (IPSS) classification; in addition, patients should never have been classified as Int-2 or High-risk since their MDS was diagnosed;

• Transfusion dependency defined by transfusion of at least 4 units of Red blood cells (RBC) within 56 days before Screening (pre-transfusion Hgb values values must be = 9 g/dL to be taken into account).

• Refractory to 8- to 12-week course of Erythropoiesis-stimulating agent (ESA) administered within the past 2 years before enrollment, or erythropoietin (EPO) level ? 500 mU/mL and off ESA for at least 8 weeks before Screening.

• Off all other treatments for MDS (azacitidine, decitabine, lenalidomide, chemotherapy, immunotherapy) for at least 2 weeks prior to Screening.

• Eastern Cooperative Oncology Group(ECOG) performance status of 0, 1 or 2.

• Willing to adhere to the prohibitions and restrictions specified in this protocol.

• The patient must signed an informed consent form (ICF) indicating that s/he understands the purpose of, and procedures required for, the study and is willing to participate.

Exclusion Criteria:

• Ongoing clinically significant anemia due to factors such as iron, vitamin B12, or folate deficiencies, auto-immune or hereditary hemolysis, or gastrointestinal (GI) bleeding.

• Serum ferritin < 50 ng/mL.

• Hypoplastic MDS (cellularity <10%)

• Any active malignancy within the past year, except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast.

• Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.

• Active infection not adequately responding to appropriate therapy.

• Total bilirubin = 2.0 mg/dL not related to hemolysis or Gilbert's disease.

• Alanine transaminase (ALT) or aspartate transaminase (AST) = 2.5 x the upper limit of normal (ULN).

• Serum creatinine = 2.0 mg/dL.

• Ascites requiring active medical management including paracentesis.

• Hyponatremia (defined as serum sodium value of < 130 mEq/L).

• Female patients who are pregnant or lactating.

• Patients of childbearing potential who are unwilling to follow strict contraception requirements.

• Female patients with reproductive potential who do not have a negative blood or urine pregnancy test at Screening.

• Major surgery without full recovery or major surgery within 3 weeks of Screening.

• Uncontrolled hypertension (defined as a systolic pressure = 160 mmHg and/or a diastolic pressure = 110 mmHg).

• New onset seizures (within 3 months prior to the first dose of rigosertib) or poorly controlled seizures.

• Any other concurrent investigational agent or chemotherapy, radiotherapy, or immunotherapy.

• Chronic use (? 2 weeks) of corticosteroids (? 10 mg/24 hr equivalent prednisone) within 4 weeks of Screening.

• Investigational therapy within 4 weeks of Screening.

• Allergy to a local anaesthetic.

• Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.

Related Conditions & MeSH terms

• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• Oral rigosertib
Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.

Locations

Country	Name	City	State
France	Hôpital Saint-Louis, Service d'Hématologie	Paris	IDF
Germany	Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden	Dresden	Saxony
Germany	Heinrich Heine Universität	Düsseldorf	NRW
Germany	Universitätsklinikum Köln	Köln	NRW
United States	Anschutz Cancer Pavilion University of Colorado	Aurora	Colorado
United States	Greenbaum Cancer Center University of Maryland	Baltimore	Maryland
United States	The University of Chicago	Chicago	Illinois
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas
United States	Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey
United States	Mount Sinai Medical Center	New York	New York
United States	Mayo Clinic	Rochester	Minnesota
United States	Stanford University School of Medicine	Stanford	California
United States	Washington Cancer Institute at Medstar Washington Hospital Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Onconova Therapeutics, Inc.

Countries where clinical trial is conducted

United States,  France,  Germany, 

References & Publications (3)

Garcia-Manero G, Fenaux P. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood Dec 2016, 128 (22) 2011; ASH 2016.

Navada SC, Silverman LR. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2016 Aug;16(8):805-10. doi: 10.1080/14737140.2016.1209413. Epub 2016 Jul 15. Review. — View Citation

Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW, Sridhar K, Wilhelm F, Greenberg PL. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res. 2012 Jan;36(1):98-103. doi: 10.1016/j.leukres.2011.08.022. Epub 2011 Sep 14. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hematologic Improvement	The number of patients who achieve hematologic improvement will be documented. Hematologic improvement is defined by the 2006 International Working Group (IWG) response criteria for the erythroid, platelet and neutrophil lineages.	24 Weeks
Secondary	Overall Response	The number of patients with a complete remission or a partial remission will be documented. Complete remission and partial remission are defined according to 2006 IWG response criteria for MDS. Overall response = complete remission + partial remission.	Up to 2 years
Secondary	Duration of Response	The number of weeks a complete remission or a partial remission is observed in a patient will be documented.	Up to 2 years
Secondary	Number of Adverse Events	Specific safety parameters and procedures will include recording of medical history, medication history, physical examination, measurement of vital signs (blood pressure, temperature, respiration rate, and pulse), weight, laboratory evaluations, and toxicity and AE assessments.	Up to 2 years